

Finnish Biomedical Start-Up Nightingale Health Obtains CE Mark for Blood Analysis Platform

publication date: Jul 27, 2017 | author/source: Nightingale Health

[Previous](#) | [Next](#)

Finnish biomedical startup Nightingale Health Ltd announced today CE marking for its blood biomarker analysis platform.

The CE mark enables the clinical use of the analysis service and the analysed measures of creatinine and glucose in the EU region.

Nightingale's goal is to bring dozens of biomarkers included in the analysis platform gradually available for clinical use within the next year. The obtained CE mark is a remarkable step towards the company's aim, enabling better prediction and targeted care for chronic diseases.

Nightingale Health's blood biomarker analysis platform is based on NMR (Nuclear Magnetic Resonance) spectroscopy. It captures over 228 metabolic biomarkers from a single blood sample, transforming the possibility to understand molecular mechanisms and treatment effects of chronic diseases, such as cardiovascular disease, diabetes, and other metabolic diseases. To date, Nightingale Health's blood biomarker analysis platform has been used by world leading medical universities and institutions and nearly half a million blood samples have been analysed with the technology. Nightingale Health's quality management system has previously been certified according to EN ISO 13485 standard.



“The CE mark verifies the performance, reliability and repeatability of our blood analysis technology for clinical use according to our quality management system. We expect a rapid entry to the clinical market across Europe”, says Mr. Teemu Suna, Nightingale Health's CEO and Co-founder. “We believe that our technology takes us one step closer to better prevention of chronic diseases. Therefore, we see this as a notable milestone, not only for our company but also for preventive medicine.”

Diabetes and cardiovascular diseases are one of the world's biggest health problems. The global burden of diabetes has been evaluated at US \$ 1.31 trillion, equivalent of 0,6 % of the world's GDP.

Nightingale Health's blood biomarker analysis platform

Nightingale Health's biomarker analysis platform provides quantification of 228 metabolic measures from single sample with one test. The metabolites are quantified in absolute concentrations (e.g. mmol/l), so they can be applied both in healthcare and in medical research. The method is fully feasible for diagnostic use of individual biomarkers, research of multiple biomarker metabolic pathways, and the risk analytics of comprehensive metabolic diseases. The now obtained CE mark covers the clinical use of creatinine and

glucose measures.

[more about nightingale](#)

Related Articles:

- [Nightingale Health Shortlisted for Finnish Health Awards 2018](#)
- [Nightingale Health and UK Biobank Announce Major Initiative to Analyse Half a Million Blood Samples to Facilitate Global Medical Research](#)
- [Bruker Announces World's First Superconducting 1.1 Gigahertz Magnet for High-Resolution NMR in Structural Biology](#)
- [Programme launched by Bioquell to help support NHS CPE toolkit](#)
- [Arcis Biotechnology and Mirnax Biosens Sign Exclusive License Agreement for Arcis Sample Prep Technology](#)
- [PredictImmune Awarded Innovate UK Grant to Apply its Biomarker-Based Technology Towards the Prediction of Drug Response in IBD](#)
- [Gustave Roussy and Protagen AG Collaborate to Improve the Risk Profiling of Cancer Patients Undergoing Immunotherapy](#)
- [Owlstone Medical Provides Breath Biopsy Services to AstraZeneca to Study Disease Drivers in Asthma and COPD](#)
- [Median Technologies to Lead a Scientific and Medical Round Table to Discuss the Application of its Groundbreaking Imaging Phenomics Platform iBiopsy for Nonalcoholic Steatohepatitis \(NASH\)](#)
- [Protagen AG Join Forces with the U.S. National Cancer Institute to Answer Pressing Questions in Immuno-Oncology](#)
- [OGT Expands NGS Offering with Targeted Familial Sequencing and Analysis](#)
- [Olink Bioscience Introduces Scalable Protein Biomarker Assays with Proseek Multiplex](#)
- [Waters Enhances its Omics Research Platform Solution with TransOmics 2.0 Informatics](#)
- [LGC acquires leading bioanalytical sciences business from Quotient Bioresearch](#)
- [Quotient discusses Biomarkers and Decision-Making in Drug Development](#)
- [Agar Scientific announces new highly concentrated colloidal gold for research applications](#)
- [OGT to Exhibit and Present at Molecular Medicine Tri-Con 2012](#)
- [ELISA kits enable precise analysis of key neurodegenerative-related biomarkers](#)
- [Protagen to Apply UNlarray Platform for Biogen Idec](#)

Newsletter Sign up

Subscribe here



Subscribe to receive our newsletters for the latest news on new laboratory products, research, Industry news and more



Weekly Update | Separation Science | Microscopy & Image Analysis | Monthly Update

Popular this Month...

Our Top 10 most popular articles this month

Today's Picks...

Looking for a Supplier?

Search by company or by product

Company Name:

Product:

SEARCH



Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

[Previous](#) | [Next](#)

[Back to top](#)